Table 4. The fold change in expression of anabolic, catabolic and hypertrophic genes in the cartilage discs from each healthy donor in response to variant A form of GDF5.

Fold change in gene expression in response to variant A form of GDF5 in healthy donors A-C
Role	Gene	Day 3			Day 7
		Donor A	Donor B	Donor C	Donor A	Donor B	Donor C
Anabolic	ACAN	0.98	0.82	0.79	0.62	1.48	0.63
	COL2A1	3.24	1.10	0.73	0.80	1.52	0.50
	SOX9	1.06	1.05	0.78	1.23	1.58	1.59
	TIMP1	0.87	1.04	1.13	0.87	1.37	1.16
Catabolic	ADAMTS4	0.83	0.86	1.05	1.26	1.00	6.64
	ADAMTS5	1.02	0.99	1.54	1.09	1.28	2.98
	MMP1	0.41	1.17	1.67	0.76	2.12	0.95
	MMP13	0.45	0.72	0.65	0.74	2.87	2.99
Hypertrophic	BGLAP	1.02	0.56	0.65	1.58	0.58	0.47
	COL1A1	1.85	1.26	0.77	1.22	2.12	0.52
	COL10A1	3.90	1.33	0.75	0.94	1.06	0.18
	IHH	6.71	1.64	0.71	0.45	1.79	0.11
	RUNX2	1.31	1.05	0.88	1.69	1.03	0.71
	RUNX2 bn	1.39	1.09	1.09	1.69	1.10	0.76

Gene expression was measured at day 3 and day 7 of chondrogenesis without exogenous GDF5 (untreated) or with variant A form of GDF5. A fold change of 1 would represent no change in target gene expression relative to untreated. A value greater than 1 (highlighted in green) denotes increased gene expression relative to untreated and a value less than 1 (highlighted in red) denotes decreased gene expression relative to untreated. RUNX2 bn, the bone specific RUNX2 transcript.